Journal of Movement Disorders

Letter to the editor

Myorhythmia and Other Movement Disorders in Two Patients With Coronavirus Disease 2019 Encephalopathy: Rebecca Hui Min Hoe, Fan Yang, Siew Kit Shuit, Glenn Khai Wern Yong, Ser Hon Puah, Jennifer Sye Jin Ting, Mucheli Sharavan Sadasiv, Thirugnanam Umapathi; J Mov Disord. 2023;16(2):217-220. Published online April 26, 2023; DOI: https://doi.org/10.14802/jmd.22215

172 View
12 Download

PDF Supplementary Material

Viewpoints

Challenges in Parkinson’s Disease Care—In Light of the COVID-19 Pandemic: Kyung Ah Woo, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2023;16(1):52-54. Published online November 10, 2022; DOI: https://doi.org/10.14802/jmd.22085

700 View
52 Download

PDF

Mask on, Mask off: Subclinical Parkinson’s Disease Unveiled by COVID-19: Milan Beckers, Bastiaan R Bloem, Rick C Helmich; J Mov Disord. 2023;16(1):55-58. Published online November 10, 2022; DOI: https://doi.org/10.14802/jmd.22067

960 View
67 Download

PDF

Letters to the editor

Catatonia in Hospitalized Patients With COVID-19: An Important Clinical Finding That Should Not be Missed: Tien Lee Ong, Sapiah Sapuan; J Mov Disord. 2022;15(3):277-280. Published online May 10, 2022; DOI: https://doi.org/10.14802/jmd.21172

1,945 View
168 Download

PDF Supplementary Material

COVID-19 Associated Acute Necrotizing Encephalopathy Presenting as Parkinsonism and Myorhythmia: Tien Lee Ong, Khariah Mat Nor, Yusniza Yusoff, Sapiah Sapuan; J Mov Disord. 2022;15(1):89-92. Published online November 17, 2021; DOI: https://doi.org/10.14802/jmd.21063

3,491 View
154 Download
8 Citations

PDF Supplementary Material

Citations

Citations to this article as recorded by

Steroid administration for post‐COVID‐19 Parkinsonism: A case report
Witoon Mitarnun, Metha Apiwattanakul, Thanatchanan Thodthasri, Praewa Tantisungvarakoon, Wilasinee Pangwong
Neurology and Clinical Neuroscience.2023; 11(1): 49. CrossRef
Limb myorhythmia treated with chemodenervation: a case report
Nil Saez-Calveras, Meredith Bryarly, Meagen Salinas
Therapeutic Advances in Neurological Disorders.2023; 16: 175628642211503. CrossRef
Parkinson’s Disease in Light of the COVID-19 Pandemic
Anna Drelich-Zbroja, Mateusz Cheda, Maryla Kuczyńska, Izabela Dąbrowska, Ewa Kopyto, Izabela Halczuk
Brain Sciences.2022; 12(2): 143. CrossRef
Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review
Jeremy M. Morowitz, Kaylyn B. Pogson, Daniel A. Roque, Frank C. Church
Brain Sciences.2022; 12(5): 536. CrossRef
Coronavirus Disease 2019 and Related Parkinsonism: The Clinical Evidence Thus Far
Iro Boura, Kallol Ray Chaudhuri
Movement Disorders Clinical Practice.2022; 9(5): 584. CrossRef
COVID-19 and Parkinsonism: A Critical Appraisal
Francesco Cavallieri, Valentina Fioravanti, Francesco Bove, Eleonora Del Prete, Sara Meoni, Sara Grisanti, Marialuisa Zedde, Rosario Pascarella, Elena Moro, Franco Valzania
Biomolecules.2022; 12(7): 970. CrossRef
Viruses, parkinsonism and Parkinson’s disease: the past, present and future
Valentina Leta, Daniele Urso, Lucia Batzu, Yue Hui Lau, Donna Mathew, Iro Boura, Vanessa Raeder, Cristian Falup-Pecurariu, Daniel van Wamelen, K. Ray Chaudhuri
Journal of Neural Transmission.2022; 129(9): 1119. CrossRef
Movement Disorders and SARS‐CoV ‐2
Wilson K.W. Fung, Alfonso Fasano, Conor Fearon
Movement Disorders Clinical Practice.2022;[Epub] CrossRef

Review Articles

Parkinson’s Disease and the COVID-19 Pandemic: A Review Article on the Association between SARS-CoV-2 and α-Synucleinopathy: Smriti Sinha, Swati Mittal, Rupali Roy; J Mov Disord. 2021;14(3):184-192. Published online July 29, 2021; DOI: https://doi.org/10.14802/jmd.21046

4,985 View
211 Download
9 Citations

Abstract PDF

There is an extensive debate on the neurological consequences of 2019 novel coronavirus disease (COVID-19) and its impact on Parkinson’s disease (PD) patients, which seems to puzzle neurologists. Links between viral infections and PD have long been suspected and studied, but the exact relationship remains elusive. Since severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) enters the brain through multiple routes and has a direct impact on the brain, cumulative damage occurs due to the activation of proinflammatory cytokines and chemokines. SARS-CoV-2 seems to aggravate PD due to its effects on α-synuclein, mitochondrial dysfunction, and dopamine depletion. A few studies have even highlighted the higher vulnerability of PD patients to COVID-19. The sudden dramatic change in lifestyle caused by the pandemic and the widespread lockdowns that were implemented have added to the hidden sorrows of PD patients, as they already have a compromised mechanism for coping with stress. This review summarizes insights from basic science and the clinical effect of SARS-CoV-2 infection on the human brain, with a specific focus on PD.

Citations

Citations to this article as recorded by

Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms
Pei Huang, Lin-Yuan Zhang, Yu-Yan Tan, Sheng-Di Chen
Translational Neurodegeneration.2023;[Epub] CrossRef
Does the SARS-CoV-2 Spike Receptor-Binding Domain Hamper the Amyloid Transformation of Alpha-Synuclein after All?
Yulia Stroylova, Anastasiia Konstantinova, Victor Stroylov, Ivan Katrukha, Fedor Rozov, Vladimir Muronetz
Biomedicines.2023; 11(2): 498. CrossRef
Sex and age affect acute and persisting COVID-19 illness
Anna Vasilevskaya, Asma Mushtaque, Michelle Y. Tsang, Batoul Alwazan, Margaret Herridge, Angela M. Cheung, Maria Carmela Tartaglia
Scientific Reports.2023;[Epub] CrossRef
Vulnerability of Parkinson’s Patients to COVID-19 and Its Consequences and Effects on Them: A Systematic Review
Sorayya Rezayi, Meysam Rahmani Katigari, Leila Shahmoradi, Mehrbakhsh Nilashi, Hélio Teive
Parkinson's Disease.2023; 2023: 1. CrossRef
COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent
Sebastián García Menéndez, Virna Margarita Martín Giménez, Michael F. Holick, Francisco J. Barrantes, Walter Manucha
Life Sciences.2022; 297: 120464. CrossRef
SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro
Zhengcun Wu, Xiuao Zhang, Zhangqiong Huang, Kaili Ma
International Journal of Molecular Sciences.2022; 23(6): 3394. CrossRef
COVID-19 and Parkinsonism: A Critical Appraisal
Francesco Cavallieri, Valentina Fioravanti, Francesco Bove, Eleonora Del Prete, Sara Meoni, Sara Grisanti, Marialuisa Zedde, Rosario Pascarella, Elena Moro, Franco Valzania
Biomolecules.2022; 12(7): 970. CrossRef
Axial Improvement after Casirivimab/Imdevimab Treatment for COVID-19 in Parkinson’s Disease
Valentina Fioravanti, Francesco Cavallieri, Alessio Di Fonzo, Giulia Toschi, Sara Grisanti, Gaetano Salomone, Mario Zappia, Franco Valzania
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.2022; : 1. CrossRef
SARS-CoV-2 mediated neurological disorders in COVID-19: Measuring the pathophysiology and immune response
Pi-Ching Hsu, Md. Shahed-Al-Mahmud
Life Sciences.2022; 308: 120981. CrossRef

Management of Parkinson’s Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination: Yue Hui Lau, Keng Ming Lau, Norlinah Mohamed Ibrahim; J Mov Disord. 2021;14(3):177-183. Published online July 29, 2021; DOI: https://doi.org/10.14802/jmd.21034

5,311 View
150 Download
4 Citations

Abstract PDF

The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) has led to a serious global health crisis. Increasing evidence suggests that elderly individuals with underlying chronic diseases, including Parkinson’s disease (PD), are particularly vulnerable to this infection. Changes in the routine care of PD patients should be implemented carefully without affecting the quality provided. The utilization of telemedicine for clinical consultation, assessment and rehabilitation has also been widely recommended. Therefore, the aim of this review is to provide recommendations in the management of PD during the pandemic as well as in the early phase of vaccination programs to highlight the potential sequelae and future perspectives of vaccination and further research in PD. Even though a year has passed since COVID- 19 emerged, most of us are still facing great challenges in providing a continuum of care to patients with chronic neurological disorders. However, we should regard this health crisis as an opportunity to change our routine approach in managing PD patients and learn more about the impact of SARS-CoV-2. Hopefully, PD patients can be vaccinated promptly, and more detailed research related to PD in COVID-19 can still be carried out.

Citations

Citations to this article as recorded by

Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review
Jeremy M. Morowitz, Kaylyn B. Pogson, Daniel A. Roque, Frank C. Church
Brain Sciences.2022; 12(5): 536. CrossRef
Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review
Jasjit S. Suri, Mahesh A. Maindarkar, Sudip Paul, Puneet Ahluwalia, Mrinalini Bhagawati, Luca Saba, Gavino Faa, Sanjay Saxena, Inder M. Singh, Paramjit S. Chadha, Monika Turk, Amer Johri, Narendra N. Khanna, Klaudija Viskovic, Sofia Mavrogeni, John R. Lai
Diagnostics.2022; 12(7): 1543. CrossRef
Movement disorders in COVID-19 times: impact on care in movement disorders and Parkinson disease
Sabrina Poonja, K. Ray Chaudhuri, Janis M. Miyasaki
Current Opinion in Neurology.2022; 35(4): 494. CrossRef
Viruses, parkinsonism and Parkinson’s disease: the past, present and future
Valentina Leta, Daniele Urso, Lucia Batzu, Yue Hui Lau, Donna Mathew, Iro Boura, Vanessa Raeder, Cristian Falup-Pecurariu, Daniel van Wamelen, K. Ray Chaudhuri
Journal of Neural Transmission.2022; 129(9): 1119. CrossRef

Letter to the editor

Resilience and Trauma among Patients with Parkinson’s Disease during the COVID-19 Pandemic: Roberto Erro, Sofia Cuoco, Emanuele Nigro, Raffaele Ragone, Paolo Barone; J Mov Disord. 2022;15(1):77-79. Published online April 26, 2021; DOI: https://doi.org/10.14802/jmd.20126

3,604 View
154 Download
1 Citations

PDF Supplementary Material

Citations

Citations to this article as recorded by

Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adults
Sofia Cuoco, Immacolata Carotenuto, Arianna Cappiello, Rossella Bisogno, Marina Picillo, Maria Teresa Pellecchia, Paolo Barone, Roberto Erro
Neurological Sciences.2022; 43(5): 3079. CrossRef

Case Report

Myoclonus-Ataxia Syndrome Associated with COVID-19: Kuldeep Shetty, Atul Manchakrao Jadhav, Ranjith Jayanthakumar, Seema Jamwal, Tejaswini Shanubhogue, Mallepalli Prabhakar Reddy, Gopal Krishna Dash, Radhika Manohar, Vivek Jacob Philip, Vikram Huded; J Mov Disord. 2021;14(2):153-156. Published online April 6, 2021; DOI: https://doi.org/10.14802/jmd.20106

5,836 View
174 Download
7 Citations

Abstract PDF Supplementary Material

Neurological manifestations of coronavirus disease (COVID-19) have increasingly been reported since the onset of the pandemic. Herein, we report a relatively new presentation. A patient in the convalescence period following a febrile illness with lower respiratory tract infection (fever, myalgia, nonproductive cough) presented with generalized disabling myoclonus, which is phenotypically suggestive of brainstem origin, along with additional truncal cerebellar ataxia. His neurology work-ups, such as brain MRI, electroencephalography, serum autoimmune and paraneoplastic antibody testing, were normal. His CT chest scan revealed right lower lung infiltrates, and serological and other laboratory testing did not show evidence of active infection. COVID-19 titers turned out to be strongly positive, suggestive of post-COVID-19 lung sequelae. He responded partially to antimyoclonic drugs and fully to a course of steroids, suggesting a para- or postinfectious immune-mediated pathophysiology. Myoclonusataxia syndrome appears to be a neurological manifestation of COVID-19 infection, and knowledge regarding this phenomenon should be increased among clinicians for better patient care in a pandemic situation.

Citations

Citations to this article as recorded by

Opsoclonus Myoclonus Ataxia Syndrome Due to SARS-CoV-2
Josef Finsterer, Fulvio A. Scorza
Neuro-Ophthalmology.2023; 47(1): 1. CrossRef
Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19
Kenta Osawa, Atsuhiko Sugiyama, Akiyuki Uzawa, Shigeki Hirano, Tatsuya Yamamoto, Masahiko Nezu, Nobuyuki Araki, Hiroki Kano, Satoshi Kuwabara
Internal Medicine.2022; 61(7): 1071. CrossRef
Post‐infectious cerebellar ataxia following COVID ‐19 in a patient with epilepsy
Sidhartha Chattopadhyay, Judhajit Sengupta, Sagar Basu
Clinical and Experimental Neuroimmunology.2022; 13(4): 323. CrossRef
Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis
Rizaldy Taslim Pinzon, Vincent Ongko Wijaya, Abraham Al Jody, Patrick Nalla Nunsio, Ranbebasa Bijak Buana
Journal of Infection and Public Health.2022; 15(8): 856. CrossRef
Anti-neuronal antibodies against brainstem antigens are associated with COVID-19
Guglielmo Lucchese, Antje Vogelgesang, Fabian Boesl, Dina Raafat, Silva Holtfreter, Barbara M. Bröker, Angela Stufano, Robert Fleischmann, Harald Prüss, Christiana Franke, Agnes Flöel
eBioMedicine.2022; 83: 104211. CrossRef
Post–COVID ‐19 Myoclonus–Ataxia Syndrome Responsive to Intravenous Immunoglobulins
Massimiliano Godani, Alessandro Beronio, Giuseppe Lanza
Movement Disorders Clinical Practice.2022;[Epub] CrossRef
Anti-GAD associated post-infectious cerebellitis after COVID-19 infection
Ahmed Serkan Emekli, Asuman Parlak, Nejla Yılmaz Göcen, Murat Kürtüncü
Neurological Sciences.2021; 42(10): 3995. CrossRef

Original Article

Telemedicine in an Academic Movement Disorders Center during COVID-19: Christine Doss Esper, Laura Scorr, Sosi Papazian, Daniel Bartholomew, Gregory Jacob Esper, Stewart Alan Factor; J Mov Disord. 2021;14(2):119-125. Published online March 18, 2021; DOI: https://doi.org/10.14802/jmd.20099

4,739 View
139 Download
10 Citations

Abstract PDF

Objective
Telemedicine has rapidly gained momentum in movement disorder neurology during the coronavirus disease (COVID-19) pandemic to preserve clinical care while mitigating the risks of in-person visits. We present data from the rapid implementation of virtual visits in a large, academic, movement disorder practice during the COVID-19 pandemic.
Methods
We describe the strategic shift to virtual visits and retrospectively examine elements that impacted the ability to switch to telemedicine visits using historical prepandemic in-person data as a comparator, including demographics, distance driven, and diagnosis distribution, with an additional focus on patients with deep brain stimulators.
Results
A total of 686 telemedicine visits were performed over a five-week period (60% of those previously scheduled for in-office visits). The average age of participants was 65 years, 45% were female, and 73% were Caucasian. Men were more likely to make the transition (p = 0.02). Telemedicine patients lived farther from the clinic than those seen in person (66.47 km vs. 42.16 km, p < 0.001), age was not associated with making the switch, and patient satisfaction did not change. There was a significant shift in the distribution of movement disorder diagnoses seen by telemedicine compared to prepandemic in-person visits (p < 0.001). Patients with deep brain stimulators were more likely to use telemedicine (11.5% vs. 7%, p < 0.001).
Conclusion
Telemedicine is feasible, viable and relevant in the care of movement disorder patients, although health care disparities appear evident for women and minorities. Patients with deep brain stimulators preferred telemedicine in our study. Further study is warranted to explore these findings.

Citations

Citations to this article as recorded by

Long‐Lasting Impact of the COVID ‐19 Pandemic on Patients with Parkinson's Disease and Their Relatives
Andreas Wolfgang Wolff, Bernhard Haller, Antonia Franziska Demleitner, Dominik Pürner, Johanna Niederschweiberer, Isabell Cordts, Erica Westenberg, Paul Lingor
Movement Disorders Clinical Practice.2023; 10(5): 819. CrossRef
Telemedicine technologies and applications in the era of COVID-19 pandemic: A systematic review
Esmaeil Mehraeen, SeyedAhmad SeyedAlinaghi, Mohammad Heydari, Amirali Karimi, Abdollah Mahdavi, Mehrnaz Mashoufi, Arezoo Sarmad, Peyman Mirghaderi, Ahmadreza Shamsabadi, Kowsar Qaderi, Pegah Mirzapour, Amirata Fakhfouri, Hadiseh Azadi Cheshmekabodi, Kimia
Health Informatics Journal.2023; 29(2): 146045822311674. CrossRef
Telemedicine in Neurology: A Scoping Review of Key Outcomes in Movement Disorders
Emily Houston, Amanda G. Kennedy, Donna O'Malley, Terry Rabinowitz, Gail L. Rose, James Boyd
Telemedicine and e-Health.2022; 28(3): 295. CrossRef
Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic
Tagore Nakornchai, Elena Conci, Anke Hensiek, J William L Brown
Postgraduate Medical Journal.2022; 98(1161): 533. CrossRef
Moving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research
B. Y. Valdovinos, J. S. Modica, R. B. Schneider
Current Neurology and Neuroscience Reports.2022; 22(2): 113. CrossRef
Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic
Shadi Ghourchian, Yasar A. Torres-Yaghi, Stuart H. Isaacson, Fernando Pagan, Kelly E. Lyons, Brian James Nagle, Sanskruti Patel, Rajesh Pahwa
Telemedicine and e-Health.2022; 28(11): 1651. CrossRef
Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study
Yaqian Xu, Megan P. Feeney, Matthew Surface, Dan Novak, Michelle S. Troche, James C. Beck, Roy N. Alcalay
Movement Disorders.2022; 37(6): 1289. CrossRef
Service process factors affecting patients’ and clinicians’ experiences on rapid teleconsultation implementation in out-patient neurology services during COVID-19 pandemic: a scoping review
Guangxia Meng, Carrie McAiney, Christopher M. Perlman, Ian McKillop, Therese Tisseverasinghe, Helen H. Chen
BMC Health Services Research.2022;[Epub] CrossRef
Telemedicine in the Management of Parkinson’s Disease: Achievements, Challenges, and Future Perspectives
Esther Cubo, Pedro David Delgado-López
Brain Sciences.2022; 12(12): 1735. CrossRef
Clinician Perceptions of the Negative Impact of Telehealth Services in the Management of Drug-Induced Movement Disorders and Opportunities for Quality Improvement: A 2021 Internet-Based Survey
Rimal Bera, Morgan Bron, Betsy Benning, Samantha Cicero, Heintje Calara, Diane Darling, Ericha Franey, Kendra Martello, Charles Yonan
Neuropsychiatric Disease and Treatment.2022; Volume 18: 2945. CrossRef

Viewpoint

Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment: Azalea Tenerife Pajo, Adrian Isidoro Espiritu, Roland Dominic Go Jamora; J Mov Disord. 2021;14(1):29-33. Published online January 12, 2021; DOI: https://doi.org/10.14802/jmd.20088

7,349 View
172 Download
1 Citations

PDF

Citations

Citations to this article as recorded by

COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study
Yvonne Teuschl, Christian Bancher, Michael Brainin, Alexandra Dachenhausen, Karl Matz, Michaela M. Pinter
Journal of Neural Transmission.2022; 129(1): 49. CrossRef

Letter to the editor

Encephalopathy and Complex Hyperkinesia in a Patient with Severe Acute Respiratory Syndrome Coronavirus-2 Infection: Wenyang Li, Elif Pinar Coskun, Rolando Berger, John Thomas Slevin, Luther Creed Pettigrew; J Mov Disord. 2021;14(2):173-175. Published online January 12, 2021; DOI: https://doi.org/10.14802/jmd.20084

3,782 View
56 Download

PDF Supplementary Material

Case Report

Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia: Emmaline Zantua Fernando, Jeryl Ritzi Tan Yu, Salvador Miclat Abad Santos, Roland Dominic Go Jamora; J Mov Disord. 2021;14(1):75-77. Published online December 7, 2020; DOI: https://doi.org/10.14802/jmd.20091

4,496 View
117 Download
2 Citations

Abstract PDF Supplementary Material

Hydroxychloroquine (HCQ) has been used as an investigational drug for patients with moderate to severe coronavirus disease 2019 (COVID-19). There have been concerns of potential harms from side effects of the drug. We present a case of a 38-year-old male who was started on HCQ for COVID-19 pneumonia. He was referred for evaluation of myoclonus of all extremities, which resolved after discontinuation of HCQ. The involuntary movements were first reported after the initiation of HCQ, persisted despite improvement in inflammatory and radiologic parameters and eventually resolved after HCQ discontinuation. This supports a possible causality related to adverse drug reactions from HCQ that have not been commonly reported.

Citations

Citations to this article as recorded by

Safety profile of COVID-19 drugs in a real clinical setting
Mei Nee Chiu, Maitry Bhardwaj, Sangeeta Pilkhwal Sah
European Journal of Clinical Pharmacology.2022; 78(5): 733. CrossRef
Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revisão de escopo
Vinícius de Mello, Vinícius de Paula Pereira, João Paulo Vilela Rodrigues, Suelem Tavares da Silva Penteado, Leonardo Régis Leira Pereira, Fabiana Rossi Varallo
Revista Panamericana de Salud Pública.2022; 46: 1. CrossRef

Brief communication

Deep Brain Stimulation Battery Exhaustion during the COVID-19 Pandemic: Crisis within a Crisis: Vikram Venkappayya Holla, Koti Neeraja, Bharath Kumar Surisetti, Shweta Prasad, Nitish Kamble, Dwarakanath Srinivas, Ravi Yadav, Pramod Kumar Pal; J Mov Disord. 2020;13(3):218-222. Published online August 31, 2020; DOI: https://doi.org/10.14802/jmd.20073

7,142 View
106 Download
5 Citations

Abstract PDF

Objective
The novel coronavirus disease (COVID-19) pandemic and public health measures to control it have resulted in unique challenges in the management of patients with deep brain stimulation (DBS). We report our experience with the management of acute worsening of symptoms due to battery exhaustion in 3 patients with DBS.
Methods
Patients with DBS for movement disorders who visited the emergency room due to battery exhaustion during the nationwide lockdown from April to May 2020 were included.
Results
Two patients with subthalamic nucleus-DBS for Parkinson’s disease (PD) and one with globus pallidus interna-DBS for generalized dystonia presented with acute worsening of symptoms due to battery exhaustion. Urgent battery replacement was performed in both patients with PD. The patient with generalized dystonia was managed with medication adjustment as he chose to defer battery replacement.
Conclusion
DBS battery replacement can be an emergency. Decisions regarding DBS battery replacement should be individualized during this COVID-19 pandemic.

Citations

Citations to this article as recorded by

Effects of COVID-19 on Synaptic and Neuronal Degeneration
Mohammed S. Alqahtani, Mohamed Abbas, Mohammad Y. Alshahrani, Khulud Alabdullh, Amjad Alqarni, Fawaz F. Alqahtani, Layal K. Jambi, Adnan Alkhayat
Brain Sciences.2023; 13(1): 131. CrossRef
Needs and Perceptions of Patients With Dystonia During the COVID-19 Pandemic: A Qualitative Framework Analysis of Survey Responses From Italy
Vittorio Rispoli, Matías Eduardo Díaz Crescitelli, Francesco Cavallieri, Francesca Antonelli, Stefano Meletti, Luca Ghirotto, Franco Valzania
Frontiers in Neurology.2022;[Epub] CrossRef
Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns
Onanong Phokaewvarangkul, Sasivimol Virameteekul, Roongroj Bhidayasiri
Parkinsonism & Related Disorders.2021; 87: 39. CrossRef
An Investigation Into Miniaturised Closed-Loop DBS Devices
Dean M. Corva, Scott D. Adams, Kevin E. Bennet, Parastoo Hashemi, Michael Berk, Abbas Z. Kouzani
IEEE Transactions on Medical Robotics and Bionics.2021; 3(3): 671. CrossRef
Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey
Carla Piano, Francesco Bove, Tommaso Tufo, Isabella Imbimbo, Danilo Genovese, Alessandro Stefani, Massimo Marano, Antonella Peppe, Livia Brusa, Rocco Cerroni, Francesco Motolese, Enrico Di Stasio, Marianna Mazza, Antonio Daniele, Alessandro Olivi, Paolo C
Frontiers in Neurology.2020;[Epub] CrossRef

Letter to the editor

COVID-19: Implications for Sudden Death in Parkinson’s Disease: Ana Claudia Fiorini, Marcelo Cunio Machado Fonseca, Carla Alessandra Scorza, Josef Finsterer, Antônio Márcio Rodrigues, Antônio-Carlos Guimarães de Almeida, Fulvio Alexandre Scorza; J Mov Disord. 2021;14(1):78-80. Published online August 31, 2020; DOI: https://doi.org/10.14802/jmd.20065

4,422 View
131 Download

PDF

First
Prev
Page of 2
Next
Last

COVID-19 in JMD